omniture
logo
Search

/DISREGARD RELEASE: Celltrion USA/

Celltrion USA
2024-08-30 08:35 1806

We are advised by Celltrion USA that journalists and other readers should disregard the news release, Celltrion USA partners with Express Scripts and Cigna Healthcare to expand access to ZYMFENTRA® (infliximab-dyyb), the first and only FDA-approved subcutaneous infliximab on their medical benefit formulary, issued 28-Aug-2024 over PR Newswire.

Source: Celltrion USA
Related Stocks:
Korea:068270
Media Room more

Celltrion presents additional data from phase III randomized controlled trials to further support biosimilarity for CT-41 (biosimilar candidate of denosumab) and CT-P47 (biosimilar candidate of tocilizumab) at American College of Rheumatology (ACR) Convergence 2024

2024-11-19 02:15
1263

ZYMFENTRA® (infliximab-dyyb) coverage continues to increase through partnership with top 3 Pharmacy Benefit Managers (PBMs)

2024-10-31 14:31
1020

Celltrion presents post hoc analysis of LIBERTY studies of ZYMFENTRA®  (infliximab-dyyb) at the American College of Gastroenterology 2024 Annual Scientific Meeting

2024-10-30 03:25
1231

Celltrion USA announces incorporation of adalimumab-aaty, a Humira® biosimilar, to the Costco Member Prescription Program

2024-08-13 07:46
1607

ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance treatment through two years for adults with moderately to severely active Crohn's disease and ulcerative colitis

2024-05-21 12:01
1711

Celltrion USA announces two-year data for ZYMFENTRA™(infliximab-dyyb) to be presented at Digestive Disease Week (DDW) 2024 Conference

2024-05-17 12:01
1564
Related News

International Genomics Conference (ICG-19) Opens at BGI Group HQ in Shenzhen

2024-11-22 21:57
2856
Professor Huanming Yang, Co-Founder of BGI Group, delivered a keynote address on milestones in genomics (PRNewsfoto/BGI Group)

FDA Granted Orphan Drug Designation of LBL-024, An Anti-PD-L1/4-1BB Bispecific Antibody Developed by Leads Biolabs, for Treatment of Neuroendocrine Cancer

2024-11-22 16:00
2047

Two In Vitro Studies on Eravacycline (XERAVA®) Presented at IDWeek, Demonstrating Its Sustained and Robust Antimicrobial Activity

2024-11-22 12:14
1599

Olverembatinib Surmounts Ponatinib and Asciminib Resistance and Is Well Tolerated in Patients With CML and Ph+ ALL: New Report in JAMA Oncology

2024-11-22 10:27
1537

poLight ASA receives purchase order for TWedge® wobulator technical samples from a top tier consumer OEM customer

2024-11-22 00:44
1223

The GenScript Biotech Global Forum Makes a Strong Debut in Europe, Highlighting Breakthroughs in Cell and Gene Therapy Development

2024-11-21 23:46
958
collection